International Floorball Federation Anti-Doping Guidelines for IFF Events Edition 2010 INTERNATIONAL FLOORBALL FEDERATION (IFF) General Information
During the IFF Events (WFC, U19 WFC, EFC and Qualifications) there will be doping control carried out.
The players, who use medications that fall under the Prohibited List, must fill in the Therapeutic Use
Exemption form with their physician. The completed TUE forms must be submitted to the IFF Head Office
at least 30 days before the event. All documents (TUE form and medical evidence attachments) must be
Information about Therapeutic Use Exemption (TUE) For substances and methods on the Prohibited List
Floorball players, like other athletes, may have illnesses or conditions that require them to take particular
medications. If the medication that an athlete is required to take to treat an illness or condition happens
to fall under the Prohibited List, a Therapeutic Use Exemption will give the athlete the authorization to
take the needed medicine. Athletes may apply for a TUE for any treatment involving a substance or
Medical evidence needed to support the diagnosis
There needs to be objective medical evidence to confirm the diagnosis and the need for treatment with a
prohibited substance. This medical evidence must be sent together with the TUE application. Medical
evidence shall include complete medical history (for example onset of the disease, family history, triggers,
severity, etc.), results of all examinations and laboratory investigations and/or the imaging studies.
Required in official IFF Events
All international level players (players in the IFF Registered Testing pool 1) or players entering in an
international IFF event (EuroFloorball Cup, WFC, U19 WFC and Qualifications), who use prohibited
substances and/or methods, must fill the TUE Form and submit the Application to the IFF. IFF is
responsible for accepting applications and granting the certificates. All TUE applications will be reviewed
by the IFF Medical Committee. If approved, the athlete can begin treatment after receiving the
authorization notice from the IFF (except in rare cases of an acute life threatening condition for which a
retroactive approval may be considered).
Sanction fee for late TUE applications
The TUE applications need to be sent to IFF at least 30 days in advance of the IFF event. The sanction fee
for the late incoming TUE applications is 100/CHF/application. The sanction fee shall be paid by the
Member Association (WFC) or Club team (EFC) of the applying athlete.
Anti-Doping Administrator Competition Assistant Alakiventie 2 +358 9 454 214 25 [email protected] Merita Bruun Kaarina Salomaa FI-00920 Helsinki, [email protected] [email protected] +358 9 454 214 50 www.floorball.org +358 9 454 214 25 +358 9 454 214 53 INTERNATIONAL FLOORBALL FEDERATION (IFF) Validity of granted TUE’s
After IFF Medical committee has reviewed a TUE application and granted a permission to use a prohibited
substance or method, the athlete will receive a TUE certificate from the IFF. The athlete should carry a
copy of the certificate with him/her in all Floorball matches. The certificate should be presented to the
doping control officer at the time of testing.
All TUE’s are granted for a limited period of time. At least 30 days before the expiry date, a new TUE
application must be sent to the IFF together with up-to-date medical evidence. The validity of the TUE is
dependent on the prohibited substance or method, but normally TUE’s are valid for 2 - 4 years.
All TUE’s granted by IFF are valid in the different national leagues around the world.
How to apply for a TUE? 1. Download and fill in the IFF TUE form with the physician
The TUE form requires both the athlete’s and the physician’s signature The TUE form can be found from IFF web page under Materials or Anti-Doping
2. Gather required medical evidence
Complete medical history (including onset of the disease, family history, triggers, severity) Results of all examinations Laboratory investigations and/or the imaging studies
3. Send the completed TUE form together with the medical evidence to the IFF
TUE’s can be sent to the IFF by fax, e-mail or post (see contacts below)
Instructions for players using asthma medication
All inhaled glucocorticosteroids are permitted out of competition and require declaration of use for in
competition use (for example in IFF events). Salbutamol and salmeterol are permitted in competition and
out of competition in dosages considered to be appropriate for the treatment of asthma (see below).
Formoterol and terbutaline require a full TUE (with medical evidence). Asthma medication declared on the doping control form
The use of salbutamol, provided the level in the urine is less than 1000 ng/ml (dosage guideline max.
1600 µg/24 h), and salmeterol by inhalation do not require a TUE, but should be declared on the doping
control form at the time of testing. These substances when used in other ways, for example orally
(tablets), are still prohibited and require TUE’s.
Inhaled Asthma medications that include salbutamol are: Airomir, Atrodual, Buventol, Ipramol, Salipra, Ventilastin and Ventoline. Inhaled Asthma medications that include salmeterol are: Seretide and Serevent. Inhaled Glucocorticosteroids do not require a Therapeutic Use Exemption (TUE), but should be declared
on the doping control form at the time of testing.
Anti-Doping Administrator Competition Assistant Alakiventie 2 +358 9 454 214 25 [email protected] Merita Bruun Kaarina Salomaa FI-00920 Helsinki, [email protected] [email protected] +358 9 454 214 50 www.floorball.org +358 9 454 214 25 +358 9 454 214 53 INTERNATIONAL FLOORBALL FEDERATION (IFF) Asthma medication requiring a TUE
Beta-2 agonists e.g. terbutaline and formoterol are prohibited and require a Therapeutic Use Exemption
(TUE). The request for a TUE should include a complete medical file with a clear explanation of why an
alternate medication is being prescribed.
Summary of requirements for the medical file in case of asthma (attach to TUE application):
1) A complete medical history 2) A comprehensive report of the clinical examinations with specific focus on the respiratory system 3) A report of spirometry with the measurement of the Forced Expiratory Volume in 1 second (FEV1) 4) If airway obstruction is present, the spirometry will be repeated after inhalation of a short acting Beta-2
agonist to demonstrate the reversibility of bronchoconstriction
5) In the absence of reversible airway obstruction, a bronchial provocation test is required to establish the
It should be noted that, at least for 2010, the intent is not to deny the use of alternate Beta-2 agonists
because there is now a permitted substitute (salbutamol/salmeterol), particularly where a treatment
regimen has already been established. For athletes newly diagnosed with asthma, permitted Beta-2
agonists should be considered as primary treatments unless otherwise justified.
Examples of Beta-2 agonists including terbutaline or formoterol: Bricanyl, Fomeda, Foradil, Formaxa Instructions for players using Glucocorticosteroids
Systemic glucocorticosteroids are prohibited in competition only. Glucocorticosteroids requiring a TUE
All glucocorticosteroids are prohibited in competition when administered by oral, intravenous, intramuscular or rectal routes and require a TUE. Glucocorticosteroids declared on the doping control form
Glucocorticosteroids used by intraarticular, periarticular, peritendinous, epidural, intradermal and inhalation routes do not require a Therapeutic Use Exemption (TUE), but should be declared on the
doping control form at the time of testing.
Topical preparations when used for auricular, buccal, dermatological (including iontophoresis/
phonophoresis), gingival, nasal, ophthalmic and perianal disorders are not prohibited and require Anti-Doping Administrator Competition Assistant Alakiventie 2 +358 9 454 214 25 [email protected] Merita Bruun Kaarina Salomaa FI-00920 Helsinki, [email protected] [email protected] +358 9 454 214 50 www.floorball.org +358 9 454 214 25 +358 9 454 214 53 INTERNATIONAL FLOORBALL FEDERATION (IFF) Instructions about Pseudoephedrine
WADA has reintroduced pseudoephedrine (PSE) to the 2010 Prohibited List as a specified stimulant
prohibited in-competition at a urinary threshold of 150μg/mL. Pseudoephedrine is commonly used for
treating allergic nasal catarrh (flu). The established threshold levels may be reached (rarely, but possibly)
by some individuals within 6-20 hours of intake of some long-lasting therapeutic formulations.
Advise athletes to stop taking PSE pills at least 24 hours before competition.
For therapeutic applications during the In-Competition period, consider the use of alternative permitted
medications upon previous consultation with a physician, or apply for a Therapeutic Use Exemption (TUE)
for the use of PSE for therapeutic purpose(s).
Pseudoephedrine products are for example: Aerinaze, Cirrus and Duact.
Read carefully the contents on the medication packaging of any preparation as the ingredients may vary
More information and answers to Anti-Doping related questions can be asked from IFF Office by e-mail or Anti-Doping information can also be found from web:
IFF web page www.floorball.org under Anti-Doping
WADA web page www.wada-ama.org under World Anti-Doping CodeUseful links WADA Prohibited substances list 2010(WADA web page Quick links Prohibited List)
Download the IFF TUE form(IFF web page Anti-Doping Therapeutic Use Exemption)
IFF Anti-Doping Regulations, edition 2010(IFF web page Anti-Doping Rules & Regulations)
Links to National Anti-Doping agencies (WADA web page Anti-Doping community NADO’s)
Anti-Doping Administrator Competition Assistant Alakiventie 2 +358 9 454 214 25 [email protected] Merita Bruun Kaarina Salomaa FI-00920 Helsinki, [email protected] [email protected] +358 9 454 214 50 www.floorball.org +358 9 454 214 25 +358 9 454 214 53
HBDI FAMILY RESOURCE QUESTIONNAIRE FOR THE GENETICS OF TYPE 1 DIABETES Section I: Contact Information Primary Family Contact ( the person filling out this questionnaire ): Name ( First, Last ): , agree to release the enclosed information to the HBDI. HBDI may release my coded, anonymous information to approved diabetes researchers. The information in this questionnai
I’d almost forgotten that I’d arranged to meet her. But as soon as I saw abeautiful girl pushing open the door, I remembered I’d told her where I hangout. Francis, the owner, often let me sit here in the Twisted Strands, a back-street café for losers, nursing the same drink for hours. She shook off the street as she paused in the doorway, trying to spot mein the shadows. Compared to ever